Shanta M. Zimmer, MD

Articles by Shanta M. Zimmer, MD

Economic Model for Emergency Use Authorization of Intravenous Peramivir

ByBruce Y. Lee, MD, MBA,Julie H. Y. Tai, MD,Rachel R. Bailey, MPH,Sarah M. McGlone, MPH,Ann E. Wiringa, MPH,Shanta M. Zimmer, MD,Kenneth J. Smith, MD, MS,Richard K. Zimmerman, MD, MPH

March 10th 2011

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

Economic Model for Emergency Use Authorization of Intravenous Peramivir

ByBruce Y. Lee, MD, MBA,Julie H. Y. Tai, MD,Rachel R. Bailey, MPH,Sarah M. McGlone, MPH,Ann E. Wiringa, MPH,Shanta M. Zimmer, MD,Kenneth J. Smith, MD, MS,Richard K. Zimmerman, MD, MPH

January 14th 2011

The US Food and Drug Administration granted emergency use authorization of intravenous neuraminidase inhibitors for patients with 2009 influenza A (H1N1), creating a need for economic studies.

Latest Updated Articles

Economic Model for Emergency Use Authorization of Intravenous Peramivir
Published: March 10th 2011 | Updated:
Economic Model for Emergency Use Authorization of Intravenous Peramivir
Published: January 14th 2011 | Updated:

Shanta M. Zimmer, MD

Articles by Shanta M. Zimmer, MD

Economic Model for Emergency Use Authorization of Intravenous Peramivir

Economic Model for Emergency Use Authorization of Intravenous Peramivir

Latest Updated Articles

Trending on AJMC

Medicaid Work Requirements Set to Leave Millions Without Insurance

Most Favored Nation Drug Pricing Moves Forward, but Experts Warn Details Are Still Missing

AMCP Nexus 2025: Advancing Health Policy and Patient Outcomes Together

Oncology Landscape Continues to Evolve With Expanded Indications, First-in-Class Therapies

Baricitinib Leads to Significant Hair Regrowth in Adolescents With Severe Alopecia Areata